SBC Medical Group Holdings Inc. (NASDAQ: SBC) has emerged from a transformative 2025 with a strengthened foundation for growth in 2026. The Japanese owner and operator of aesthetic medical clinics expanded its franchise network to 258 locations, a 15% year-over-year increase as of September 30, 2025. This expansion was accompanied by a revised pricing strategy that boosted average revenue per customer by 5% in the third quarter, underscoring the company's ability to attract higher-spending clients through its multi-brand approach.
Key initiatives included the launch of new brands such as "Neo Skin Clinic" and "Hada no Aozora Clinic" in Tokyo, the latter integrating insurance-covered general dermatology with private-pay aesthetic treatments. Internationally, SBC entered Singapore and Thailand, and in early 2026, announced its first U.S. expansion. The company also acquired MB Career Lounge Co. Ltd., a provider of management support services for medical institutions, and Waqoo, a subsidiary focused on R&D in clinical areas like AGA and orthopedics. These moves are designed to enhance SBC's competitive position and broaden its service offerings, which now include plastic surgery and infertility treatment.
Financially, SBC reported a significant improvement in net profit for the third quarter of 2025, driven by a return to normal cost structures after IPO-related expenses. Average revenue per visit rose 5% sequentially to $298, and 8.4% from the first quarter. The company ended the quarter with a 72% repeat customer rate, highlighting strong loyalty. SBC's inclusion in the Russell 3000 Index in 2025 further elevated its visibility among institutional investors, with approximately $18.1 trillion in assets benchmarked against Russell indexes globally. The company also authorized a stock buyback of up to $5 million, signaling confidence in its growth trajectory.
To capitalize on cosmetic tourism, SBC is targeting Chinese consumers visiting Japan for procedures, enhancing its services with Chinese-speaking staff and social media outreach. In Singapore, it expanded collaboration with Aesthetic Healthcare Holdings Pte. Ltd., while in Thailand, it signed an e-consulting agreement with BLEZ ASIA Co. Ltd. to support a new dermatology clinic in Bangkok. These steps are part of a broader Asia expansion strategy aimed at capturing demand from affluent medical tourists.
The global cosmetic surgery and procedure market, valued at $122.08 billion in 2022, is expected to grow at a CAGR of 14.7% through 2030. SBC Medical, with its expanded network, diversified services, and strategic acquisitions, is well-positioned to leverage this growth. As the company enters 2026, its focus remains on capitalizing on the demand from both domestic and international clients, building on the momentum of a year defined by strategic expansion and operational improvements.
